187868-53-7

Basic information

• Product Name: Propanedioic acid, (acetylamino)-, monoethyl ester, (+)- (9CI)
• Synonyms: Propanedioic acid, (acetylamino)-, monoethyl ester, (+)- (9CI)
• CAS NO: 187868-53-7
• Molecular Formula: C₇H₁₁NO₅
• Molecular Weight: 0
• Mol File: 187868-53-7.mol
• Article Data: 9

Chemical Properties

• Appearance: /
• CAS DataBase Reference: Propanedioic acid, (acetylamino)-, monoethyl ester, (+)- (9CI)(CAS DataBase Reference)
• NIST Chemistry Reference: Propanedioic acid, (acetylamino)-, monoethyl ester, (+)- (9CI)(187868-53-7)
• EPA Substance Registry System: Propanedioic acid, (acetylamino)-, monoethyl ester, (+)- (9CI)(187868-53-7)

Safety Data

• Hazardous Substances Data: 187868-53-7(Hazardous Substances Data)

Upstream product

• 1068-90-2 2-acetylaminomalonic acid diethyl ester 

Downstream Products

• 109038-04-2 N-Acetyl-3-<4-carbomethoxy-phenyl>-serin-ethylester 
• 5872-81-1 N-Acetyl-3-(2-nitro-phenyl)-serin-ethylester 
• 95174-91-7 N-Acetyl-oxamidsaeure-ethylester-(2-chlor-phenylhydrazon) 
• 105540-35-0 N-Acetyl-oxamidsaeure-ethylester-(2-nitro-phenylhydrazon) 
• 93003-95-3 Acetamino--essigsaeure-ethylester 
• 5431-93-6 ethyl 2-(acetylamino)-3-oxobutanoate 
• 57332-78-2 5-methyl-2-thioxo-2,3-dihydro-1H-imidazole-4-carboxylic acid ethyl ester 

Relevant articles and documents

-

-

Stereoselective synthesis of dehydroamino acids using malonic acid half oxyester and aromatic aldehydes

An efficient and direct approach was developed for the synthesis of α,β-dehydroamino acid derivatives with a broad range of substrates. Amido-substituted Malonic Acid Half Oxyesters (MAHOs) have proven to be excellent partners of various aromatic aldehyde

MACROCYCLIC HEPATITIS C PROTEASE INHIBITORS

The present invention provides novel macrocyclic compounds that mimic peptide substrates of the hepatitis C viral protease and inhibit the viral protease, more particularly as inhibitors of the NS3 serine protease from hepatitis C virus. Methods for synthesis of the compounds are also provided. The compounds find utility as antiviral agents directed at hepatitis C. The invention further provides methods of employing such inhibitors, alone or in combination with other therapeutic agents, to treat hepatitis C infection in a subject in need of such treatment.